ViiV Healthcare announces U.S. approval of Tivicay® (dolutegravir) for the treatment of HIV-1

ViiV Healthcare is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved Tivicay® (dolutegravir) 50-mg tablets.
Source: GSK news - Category: Pharmaceuticals Source Type: news